US 12,221,491 B2
PSMD9 inhibitors for the treatment of hepatic lipid dysregulation
Anna Christine Drew, Cheltenham (AU); Brian Gary Drew, Cheltenham (AU); Thomas de Aguiar Vallim, Los Angeles, CA (US); and David James, Clontarf (AU)
Assigned to Baker Heart and Diabetes Institute, Melbourne (AU); The Regents of the University of California; and The University of Sydney, Sydney (AU)
Appl. No. 15/733,398
Filed by Baker Heart and Diabetes Institute, Melbourne (AU); The Regents of the University of California, Oakland, CA (US); and The University of Sydney, Sydney (AU)
PCT Filed Jan. 21, 2019, PCT No. PCT/AU2019/050033
§ 371(c)(1), (2) Date Jul. 20, 2020,
PCT Pub. No. WO2019/140488, PCT Pub. Date Jul. 25, 2019.
Claims priority of provisional application 62/619,480, filed on Jan. 19, 2018.
Prior Publication US 2021/0095048 A1, Apr. 1, 2021
Int. Cl. C07K 16/40 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01); A61K 31/713 (2006.01); A61K 39/00 (2006.01); A61P 1/16 (2006.01); C12N 15/86 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 31/7115 (2013.01); A61K 31/712 (2013.01); A61K 31/7125 (2013.01); A61K 31/713 (2013.01); A61P 1/16 (2018.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01)] 16 Claims
 
1. A method for treating a subject suffering from hepatic lipid dysregulation or at risk of suffering from same, comprising administering a PSMD9 inhibitor to the subject, wherein the PSMD9 inhibitor is or comprises a polynucleotide, wherein the polynucleotide is a modified oligonucleotide targeting PSMD9.